结直肠癌免疫检查点治疗现状与展望  

Current status and prospect of immune checkpoint therapy on colorectal cancer

作　　者：束琳 李炫飞 冯茂辉[1] Shu Lin;Li Xuanfei;Feng Maohui(Department of Gastrointestinal Surgery,Zhongnan Hospital of Wuhan University,Clinical Medical Research Center of Peritoneal Cancer of Wuhan,Clinical Cancer Study Center of Hubei Province,Key Laboratory of Tumor Biological Behavior of Hubei Province,Wuhan 430071,China)

机构地区：[1]武汉大学中南医院胃肠外科武汉市腹膜癌临床医学研究中心湖北省肿瘤医学临床研究中心肿瘤生物学行为湖北省重点实验室,430071

出　　处：《中华实验外科杂志》2022年第10期2037-2039,共3页Chinese Journal of Experimental Surgery

基　　金：国家自然科学基金(82070302、1902018);武汉市腹膜癌临床医学研究中心资助项目(2015060911020462);武汉大学中南医院科技创新培育基金资助项目(CXPY2022055)。

摘　　要：免疫检查点抑制剂(ICIs)的出现,开启了肿瘤免疫治疗的新时代。对于高度微卫星不稳定(MSI-H)结直肠癌患者,ICIs往往有较好疗效,其临床应用也逐渐从晚期后线移至一线治疗;然而对于微卫星稳定(MSS)结直肠癌患者,ICIs单药并无明显作用。近年来,随着ICIs联合放化疗等治疗方案的应用,ICIs治疗MSS型结直肠癌患者效果得到改善。本文拟对近年来免疫检查点治疗在结直肠癌上的应用进行总结与展望。The emergence of immune checkpoint inhibitors(ICIs)has opened a new era of tumor immunotherapy.For patients with high microsatellite instability(MSI-H)colorectal cancer,the treatment of ICIs can have a stable effect,and the treatment regimen has gradually moved from the late stage to the first-line treatment.However,for patients with microsatellite stability(MSS)colorectal cancer,ICIs alone has no significant effect.In recent years,with the application of ICIs combined with chemoradiotherapy and other treatment regimens,the efficacy of ICIs in the treatment of colorectal cancer patients with MSS has been improved.This article aims to summarize and prospect the application of immune checkpoint therapy in colorectal cancer in recent years.

关 键 词：结直肠癌 免疫检查点抑制剂 高度微卫星不稳定 

分 类 号：R735.34[医药卫生—肿瘤]